Medtronic Stock Price, News & Analysis

Medtronic has received FDA 510(k) clearance for its INVOS™ 7100 system, facilitating enhanced monitoring of organ-specific oxygen levels in pediatric patients from birth to 18 years. This system is designed to alert clinicians to critical changes in patient conditions, aiding in timely interventions for vulnerable neonates and children. With real-time measurements of tissue perfusion and oxygenation, the INVOS™ 7100 is expected to improve clinical outcomes. The technology will be commercially available in spring 2022.

Medtronic plc (NYSE: MDT) announced a study in Osteoporosis International showing significant reductions in oral opioid use and payer costs after balloon kyphoplasty (BKP) or vertebroplasty (VP) for vertebral compression fractures (VCF). Of patients studied, 57.1% decreased opioid use, with an average payer cost savings of $6,759 over six months. The findings suggest potential benefits in managing pain and reducing opioid reliance in patients. This is the first study prioritizing opioid reduction as a primary outcome.

Medtronic plc (NYSE:MDT) announced a $0.63 cash dividend for Q3 of fiscal 2022, marking a 9% increase from the previous year. This increase reinforces its position as a member of the S&P 500 Dividend Aristocrats, with 44 consecutive years of dividend growth. The dividend will be payable on January 14, 2022, to shareholders of record by December 22, 2021. Medtronic is recognized for its innovative healthcare solutions and has a workforce of over 90,000 globally.

Medtronic (NYSE:MDT) reported a second-quarter revenue of $7.847 billion, up 3% year-over-year, with organic growth of 2%. GAAP diluted EPS was $0.97, a 169% increase. Second-quarter U.S. revenue of $3.997 billion declined 1%, while emerging markets surged 20%. The company revised fiscal year 2022 organic revenue growth expectations to 7-8% from 9%. Despite challenges from COVID-19 and labor shortages affecting procedures, Medtronic remains optimistic about growth due to a strong pipeline and operational improvements.

Medtronic (NYSE:MDT) has received FDA 510(k) clearance for its PillCam™ Small Bowel 3 system, enabling remote endoscopy procedures through the PillCam SB3 @HOME program. This innovation allows patients to undergo telehealth procedures for detecting gastrointestinal issues such as Crohn's disease and obscure bleeding from home. The system captures approximately 50,000 images during the procedure, which are securely transmitted for diagnostic review, enhancing patient safety and convenience. This marks a significant development in remote healthcare technology, especially post-pandemic.

Medtronic plc (NYSE:MDT) announced four key executive appointments to enhance its healthcare technology leadership. Bob Hopkins becomes head of global strategy, Mei Jiang takes on the role of global digital innovation leader, while Harry 'Skip' Kiil and Mira Sahney will lead the Cranial and Spinal Technologies and Pelvic Health Operating Units, respectively. These appointments aim to bring diverse expertise and accelerate innovation in a rapidly evolving medical technology landscape, furthering Medtronic's mission to deliver transformative healthcare solutions.

Medtronic plc (NYSE:MDT) will announce its financial results for Q2 FY2022 on November 23, 2021, at approximately 5:45 a.m. CST. The results will cover the quarter ending October 29, 2021. A video webcast to discuss these results will take place at 7:00 a.m. CST on the same day. Medtronic is scheduled to report its Q3 and Q4 results in February and May 2022, respectively. The company, based in Dublin, focuses on healthcare technology solutions, aiming to alleviate pain and restore health.